The privatization of pharmaceutical companies in Romania is due to start on a major scale on July 1, and is likely to proceed quickly, reports the Rompres news agency. The privatization is open to domestic and foreign investors.
Production by Romanian drug firms is based on domestic raw materials and geared towards the home market. The industry is said to have the advantages of a fast circulation of capital, few financial problems and an attraction for foreign investors. For example, Canadian businessmen expressed interest in investing in the industry during a visit by a Romanian delegation to Canada recently; more detailed follow-up talks on this are expected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze